214 related articles for article (PubMed ID: 36925390)
1. SOHO State-of-the-Art Updates and Next Questions | BCMA-Directed CAR T-Cells: Early Results and Future Directions.
Biltibo E; Berdeja JG
Clin Lymphoma Myeloma Leuk; 2023 May; 23(5):310-321. PubMed ID: 36925390
[TBL] [Abstract][Full Text] [Related]
2. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
3. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
Davis JA; Shockley A; Hashmi H
J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
[TBL] [Abstract][Full Text] [Related]
4. B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma.
Abramson HN
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707894
[TBL] [Abstract][Full Text] [Related]
5. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
[TBL] [Abstract][Full Text] [Related]
6. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma.
Yang J; Zhou W; Li D; Niu T; Wang W
Cancer Lett; 2023 Jan; 553():215949. PubMed ID: 36216149
[TBL] [Abstract][Full Text] [Related]
7. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
[TBL] [Abstract][Full Text] [Related]
8. [CAR-T cells immunotherapy in multiple myeloma: Present and future].
Ferment B; Arnulf B
Bull Cancer; 2021 Oct; 108(10S):S65-S72. PubMed ID: 34920809
[TBL] [Abstract][Full Text] [Related]
9. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
[TBL] [Abstract][Full Text] [Related]
10. High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma.
Tang Y; Yin H; Zhao X; Jin D; Liang Y; Xiong T; Li L; Tang W; Zhang J; Liu M; Yu Z; Liu H; Zang S; Huang Z
J Exp Clin Cancer Res; 2022 Jan; 41(1):2. PubMed ID: 34980210
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma.
Rujirachaivej P; Siriboonpiputtana T; Luangwattananun P; Yuti P; Wutti-In Y; Choomee K; Sujjitjoon J; Chareonsirisuthigul T; Rerkamnuaychoke B; Junking M; Yenchitsomanus PT
Clin Exp Med; 2024 Apr; 24(1):90. PubMed ID: 38683232
[TBL] [Abstract][Full Text] [Related]
12. Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma.
Yuti P; Sawasdee N; Natungnuy K; Rujirachaivej P; Luangwattananun P; Sujjitjoon J; Yenchitsomanus PT
Biomed Pharmacother; 2023 Dec; 168():115691. PubMed ID: 37844355
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting.
Xia J; Li Z; Xu K
J Hematol Oncol; 2023 Jun; 16(1):60. PubMed ID: 37277826
[TBL] [Abstract][Full Text] [Related]
14. BCMA CAR-T cells in multiple myeloma-ready for take-off?
Scheller L; Tebuka E; Rambau PF; Einsele H; Hudecek M; Prommersberger SR; Danhof S
Leuk Lymphoma; 2024 Feb; 65(2):143-157. PubMed ID: 37997705
[TBL] [Abstract][Full Text] [Related]
15. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.
Smith EL; Harrington K; Staehr M; Masakayan R; Jones J; Long TJ; Ng KY; Ghoddusi M; Purdon TJ; Wang X; Do T; Pham MT; Brown JM; De Larrea CF; Olson E; Peguero E; Wang P; Liu H; Xu Y; Garrett-Thomson SC; Almo SC; Wendel HG; Riviere I; Liu C; Sather B; Brentjens RJ
Sci Transl Med; 2019 Mar; 11(485):. PubMed ID: 30918115
[TBL] [Abstract][Full Text] [Related]
16. Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting.
Guo R; Lu W; Zhang Y; Cao X; Jin X; Zhao M
Front Immunol; 2022; 13():839097. PubMed ID: 35320942
[TBL] [Abstract][Full Text] [Related]
17. BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting.
Wu JF; Dhakal B
J Hematol Oncol; 2023 Jul; 16(1):86. PubMed ID: 37507805
[TBL] [Abstract][Full Text] [Related]
18. An Overview of CAR T Cell Mediated B Cell Maturation Antigen Therapy.
Quazi S
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):e392-e404. PubMed ID: 34992008
[TBL] [Abstract][Full Text] [Related]
19. Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma.
Poels R; Drent E; Lameris R; Katsarou A; Themeli M; van der Vliet HJ; de Gruijl TD; van de Donk NWCJ; Mutis T
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499253
[TBL] [Abstract][Full Text] [Related]
20. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.
Feng D; Sun J
Scand J Immunol; 2020 Aug; 92(2):e12910. PubMed ID: 32471019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
